Heart Rate Variability and Its Relation to Chronic Kidney Disease: Results From the PREVEND Study

Christian H.L. Thio, MSc, Arie M. van Roon, PhD, Joop D. Lefrandt, MD, PhD, Ron T. Gansevoort, MD, PhD, and Harold Snieder, PhD

ABSTRACT

Objective: In the general population, reduced heart rate variability (HRV) has been associated with cardiovascular disease. However, its relation to chronic kidney disease (CKD) is debated. We therefore investigated the relation between low HRV and renal outcomes.

Methods: In the population-based Prevention of REnal and Vascular ENdstage Disease study, renal outcomes (CKD, estimated glomerular filtration rate [eGFR], urinary albumin) were measured at baseline and three consecutive examinations. HRV measures (among which SDNN [standard deviation of normal-to-normal RR intervals]) were calculated from time series of beat-to-beat pulse wave recordings at baseline. The lowest (risk) quartile was compared with the upper three quartiles combined, in multivariable survival and linear mixed-effects analyses.

Results: In 4605 participants (49% males, age range = 33–80, 0.6% blacks), we observed 341 new participants of CKD during a median follow-up duration of 7.4 years. Low SDNN was associated with higher incidence of CKD (crude HR = 1.66, 95% CI = 1.30 to 2.12, \( p < .001 \)), but this association was no longer significant after adjustment for age, sex, and cardiovascular risk factors (adjusted HR = 1.13, 95% CI = 0.86 to 1.48, \( p = .40 \), similar for other HRV measures). No associations between SDNN and eGFR trajectories were found in the total sample. However, in a subgroup of participants with baseline CKD (n = 939), we found a significant association of low SDNN (but not other HRV measures) with lower baseline eGFR, even after multivariable adjustment (adjusted \( \beta_{\text{level difference}} = -3.73 \) ml/min/1.73 m\(^2\), 95% CI = –6.70 to –0.75, \( p = .014 \)), but not with steeper eGFR decline.

Conclusions: These results suggest that reduced HRV may be a complication of CKD rather than a causal factor.

Key words: chronic kidney disease, heart rate variability, longitudinal study, renal function decline.

INTRODUCTION

Chronic kidney disease (CKD) is a group of heterogeneous disorders characterized by kidney damage and impaired renal function and is defined by an elevated urinary albumin excretion (UAE), a decreased glomerular filtration rate (GFR), or a combination of both (1–3). The most important risk factors for CKD are diabetes and hypertension. However, it has been observed that CKD can also occur in the absence of these risk factors (4,5). This suggests that other mechanisms may be involved in the development of CKD.

A potential causal mechanism involves imbalance of the autonomic nervous system, in which parasympathetic function is decreased relative to sympathetic function. Hypothetically, autonomic imbalance causes renal damage through changes in renal hemodynamics. In animal studies, stimulation of renal sympathetic afferents affected renal hemodynamics, whereas renal (sympathetic) denervation in these animals attenuated progression of kidney failure (6–8). In humans, a noninvasive way of assessing autonomic function is by calculating heart rate variability (HRV), a measure of autonomic control over heart rate. It is the variation in duration between normal-to-normal (NN) RR intervals (9–12). Moderate-to-high HRV indicates healthy autonomic function, whereas low HRV reflects poor autonomic function and has been associated with cardiovascular risk factors and adverse cardiovascular outcomes (10,11,13–16). The relation between HRV and CKD has been explored in several small-scale studies. Participants with CKD were found to have lower HRV compared with...
those without CKD. In addition, low HRV was associated with adverse outcomes during follow-up (i.e., progression to end-stage renal disease and mortality) in CKD patients, although results are inconsistent between studies (17–23). The mechanisms underlying this association are still under investigation, but it is commonly believed that autonomic imbalance is a complication of renal damage (24).

However, in the Atherosclerosis Risk in Communities (ARIC) cohort, a 20% to 108% higher incidence of CKD-related hospitalization and/or end-stage renal disease (ESRD) was observed in those with low HRV (first quartile) compared with those with normal-to-high HRV (upper three quartiles combined), even in participants with normal kidney function at baseline (25). This suggests that autonomic imbalance may also play a role in the pathophysiology of CKD. To our knowledge, this finding has not yet been verified in other population-based longitudinal studies. If autonomic imbalance is identified as a mechanism of renal damage, this may lead to improved risk prediction and novel therapeutic options.

In this study, our primary aim was therefore to investigate the association between HRV and new-onset CKD in a sample of the general population. Furthermore, we assessed whether low HRV was associated with baseline levels of eGFR and UAE and change in these parameters during follow-up.

METHODS

Study Sample and Design

We used data from the Prevention of Renal and Vascular Endstage Disease (PREVEND) cohort study. Details of this study have been described elsewhere (26). In brief, 8592 individuals, sampled from the general population of Groningen, the Netherlands, completed an extensive examination between 1997 and 1998. The second, third, fourth, and fifth examination were completed in 2003, 2006, 2008, and 2012, respectively. For the present study, we refer to the second examination as “baseline,” because this was the first examination that included additional beat-to-beat blood pressure recordings that were used for calculation of HRV parameters. This examination was attended by 6894 participants, of which 2289 had missing HRV measures (because of either technical failure or poor quality signal or excessive amount of artifacts in the recording [n = 1892]), leaving 4605 participants for the present analyses. All participants gave written informed consent. The PREVEND Study was approved by the medical ethics committee of the University Medical Center Groningen and conducted in accordance with the Helsinki Declaration guidelines.

Measurement

HRV Measures

Details of the HRV measurement procedure in the PREVEND study have been described previously (27). In brief, participants were measured in a supine position, in a quiet room kept at a constant temperature of 22°C. Participants were not allowed to talk or move during the procedure. Beat-to-beat heart rate was assessed by noninvasive 15-minute pulse wave measurements using a Portapres device (FMS Finapres Medical Systems BV, Amsterdam, the Netherlands) (28) at baseline. From these 15-minute measurements, we selected the last 4 to 5 minutes of stationary time series of pulse wave data. Using CARSPAN v2.0 software (29), these time series were visually preprocessed to exclude cardiac arrhythmias, artefacts, electrical “noise,” or aberrant beats. NN RR intervals from the beat-to-beat pulse wave signals were detected with an accuracy of 5 ms (sampling frequency of 200 Hz). Artifacts were removed and the resulting gaps interpolated as described previously (30). After preprocessing, HRV measures were calculated using the same CARSPAN software. HRV measures included standard deviation of NN RR intervals (SDNN) and root mean square of successive differences between NN RR intervals (rMSSD). To quantify cyclic changes in heart rate, we calculated high-frequency (HF) and low-frequency (LF) power (area under the power spectral density curve) by Fourier spectral analysis, and the ratio between LF/ HF. LF power was defined as the total area between 0.04 and 0.15 Hz, and HF power was defined as the total area between 0.15 and 0.40 Hz (9–12). HRV was categorized into low (lowest quartile, Q1) and moderate-to-high (upper three quartiles combined, Q2–Q4) to allow direct comparison with the work of Brotman et al (25).

Renal Outcomes

Details of the assessment of eGFR and UAE have been described elsewhere (31). In brief, participants collected two consecutive 24-hour urine specimens at each screening round. The collected urine was stored cold (4°C) for a maximum of 4 days before handing it in. After this, urine specimens were stored at −20°C. Furthermore, fasting blood samples were obtained and stored at −80°C.

Measurement of serum creatinine was performed by an enzymatic method on a Roche Modular analyzer using reagents and calibrators from Roche (Roche Diagnostics, Mannheim, Germany), with intra- and interassay coefficients of variation of 0.9% and 2.9%, respectively. Serum cystatin C concentration was measured by a Gentian cystatin C Immunoassay (Gentian AS Moss, Norway) on a Modular analyzer (Roche Diagnostics). Cystatin C was calibrated directly using the standard supplied by the manufacturer (traceable to the International Federation of Clinical Chemistry Working Group for Standardization of Serum Cystatin C) (32). The intra- and interassay coefficients of variation were less than 4.1% and less than 3.3%, respectively. Urinary albumin concentration (UAC) was measured by nephelometry with a lower threshold of detection of 2.3 mg/l and intra- and interassay coefficient of variation of 2.2% and 2.6%, respectively (Dade Behring Diagnostic, Marburg, Germany). UAC was multiplied by urine volume to obtain a value of UAE in milligram per 24 hours. The two 24-hour UAE values of each subject per examination were averaged. eGFR was calculated according to the 2012 CKD-EPI creatinine-cystatin C equation (33). CKD was defined as an eGFR < 60 ml/min/1.73 m², a UAE of 30 mg/24 hours or greater, or both, according to the 2011 revised Kidney Disease: Improving Global Outcomes guidelines (2).

Covariates

Known cardiovascular risk factors were included as covariates and assessed at baseline. Body mass index (weight/height²) and waist-hip circumference ratio were calculated from anthropometrics. Mean interbeat interval was calculated from time series of beat-to-beat heart rate data. Smoking status was defined as self-reported never, former, or current smoker (subdivided in <6 cigarettes, 6–20 cigarettes, and >20 cigarettes daily). History of cardiovascular disease (CVD) was assessed using questionnaires and was defined as a history of any cardio- or cerebrovascular events. Hypertension was defined as SBP of 140 mm Hg or greater, DBP of 90 mm Hg or greater, or self-reported or pharmacy-reported prescribed use of blood pressure-lowering drugs, including ACE inhibitors, angiotensin II receptor antagonists, β-blocking agents, and diuretics (ATC codes C, 3, 7, 8, 9). Diabetes was defined as either a fasting glucose level of greater than 7 mmol/l or self-reported or pharmacy-reported prescribed use of antidiabetic drugs. Hypercholesterolemia was defined as a total cholesterol of 6.21 mmol/l or greater or self-reported or pharmacy reported prescribed use of lipid-lowering drugs.

Statistical Analysis

Statistical analyses were performed using SPSS Version 22.0 (IBM Corporation). Two-sided significance level was set at α level of 0.05.

Baseline Characteristics

Baseline characteristics were compared between HRV categories using Student’s t tests, Mann-Whitney U tests, and χ² tests where appropriate.
Association of HRV With CKD Incidence

For this analysis, participants with CKD (n = 939) or unknown CKD status at baseline (n = 269) were excluded. Participants were censored at death, loss to follow-up, withdrawal, or end of study. We used midpoint imputation to approximate time to event (34). Mantel-Cox log-rank tests were performed to test for equality in hazard rates between low HRV and moderate-to-high HRV. In Cox regression models, we adjusted for potential confounders by introducing blocks of covariates. Block 1 included age; block 2 additionally included sex, body mass index, waist-hip circumference ratio, mean interbeat interval, smoking, baseline eGFR, and baseline UAE; block 3 additionally included a history of CVD, diabetes, hypertension, and hypercholesterolemia. All covariates were retained in the model; no criteria for covariate exclusion were applied.

Association of HRV With Baseline Levels and Change in eGFR and UAE

To examine the association of baseline HRV with eGFR and UAE over time, we conducted multivariable linear mixed-effects analyses in the entire sample (N = 4605). eGFR and the natural logarithm of UAE were modeled as a function of time. Based on model-fit criteria and likelihood ratio tests, we specified a base model with unstructured covariance structure, random intercept, and random slope for time.

HRV category (Q1 versus Q2–Q4) was added to the model to assess its association with baseline eGFR and UAE. A two-way interaction between HRV and time was introduced to assess the association of HRV with change in eGFR (ml/min/1.73 m² per year) and UAE (mg/24 hours per year). In multivariable models, we adjusted for incremental blocks of covariates as described previously.

Sensitivity Analyses

By design, participants with a moderately elevated UAC (>10 mg/l) are overrepresented in the PREVEND study. To address this imbalance, we performed sensitivity analyses using statistical weights that were based on the selection probability. In addition, we performed 40 imputations using the fully conditional specification method (35,36), by which we imputed missing HRV and covariate data. Additional analyses included definitions of new-onset CKD based on either impaired eGFR only (CKD_eGFR: eGFR < 60 ml/min/1.73 m²) or elevated UAE only (CKD_UAE: UAE ≥ 30 mg/24 hours). Furthermore, we applied a stricter definition of the high-risk group by assigning to it participants that were in Q1 of each of the three main HRV parameters, SDNN, rMSSD, and HF (“Composite low HRV”, see Figure S1, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A436). We excluded those with CKD or unknown CKD status at baseline, leaving 3397 participants. Baseline characteristics for these 3397 participants are presented in Table S1b-c, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A436. Of these participants, 341 developed CKD during a median (IQR) of 7.4 (7.0–7.8) years of follow-up. At the earliest moment of identification, those with new-onset CKD had mildly diminished eGFR (M [IQR] = 79 [59–94]), eGFR < 60 in 20% and elevated UAE (M [IQR] = 35 [17–48]), UAE ≥ 30 in 72% (see Table S2, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A436). Event rates of CKD per HRV category are shown in Table 3. Incidence rate of CKD was significantly higher in those with low HRV (SDNN Q1 versus Q2–Q4: 29.1 versus 16.7 participants per 1000 person-years, Mantel-Cox log-rank test χ² = 23.9, df = 1, p < .001, similar for other HRV measures). The results of Cox regression analyses are shown in Table 4 (results for LF, LF/HF ratio in Table S4a, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A436). Low HRV was associated with CKD incidence (SDNN Q1 versus Q2–Q4: unadjusted hazard ratio [HR] = 1.66, 95% CI = 1.30 to 2.12, similar for other HRV measures). After adjusting for confounders, this association was no longer significant (SDNN Q1 versus Q2–Q4: fully adjusted HR = 1.13, 95% CI = 0.86 to 1.48, similar for rMSSD, HF, and LF). Only for LF/HF ratio, a significant association was found, which remained after multivariable adjustment (LF/HF ratio Q1 versus Q2–Q4: fully adjusted HR = 1.32, 95% CI = 1.01 to 1.71, p < .043). Alternative definitions of new-onset CKD (incidence of either impaired eGFR or of elevated UAE) yielded similar results (Table 4).

Sensitivity analyses in imputed data sets (in which we imputed missing values of HRV and covariates) and analyses with sampling weights (to account for sampling imbalance) did not substantially change results for SDNN, rMSSD, HF, and LF (see Tables S4b-d, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A436). However, the multivariable-adjusted HR for LF/HF ratio was no longer significant in these analyses (LF/HF ratio Q1 versus Q2–Q4: fully adjusted HR = 1.19, 95% CI = 0.79 to 1.79, in imputed data sets, similar for weighted analysis). Furthermore, a more stringent definition of the high-risk group (“Composite low HRV,” participants in Q1 of each of the main HRV parameters, SDNN, rMSSD, and HF, see Table 4a, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A436) yielded similar results.

Association of HRV With Baseline Levels and Change in eGFR and UAE

In Table 5, the results of linear mixed-effects analyses are shown for all 4605 participants (for LF and LF/HF ratio) (see Table S5a, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A436). Those with low HRV had significantly lower baseline eGFR and the natural logarithm of UAE.
### TABLE 1. Baseline Characteristics by Heart Rate Variability Categories (Q1 Versus Q2–Q4) for the Entire Sample

| SDNN | nMSSD | HF |
|------|-------|----|
|      | Q1 4.6–23 ms | Q2–Q4 23–262 ms | p | Q1 6.4–17 ms | Q2–Q4 17–377 ms | p | Q1 3.9–94 ms² | Q2–Q4 >94 ms² | p |
| n    | 4605 | 1151 | 3454 | NA | 1151 | 3454 | NA | 1151 | 3454 | NA |
| Age, y | 53 (45–63) | 61 (53–70) | 50 (43–59) | <.001* | 60 (52–69) | 51 (43–60) | <.001* | 60 (53–69) | 51 (43–59) | <.001* |
| Males, n (%) | 2270 (49%) | 592 (51%) | 1678 (49%) | .094 | 527 (46%) | 1808 (52%) | <.001* | 519 (45%) | 1816 (53%) | <.001* |
| Current, n (%) | 1298 (29%) | 374 (33%) | 924 (27%) | 4.6 (23–262 ms) | 23 (9.6) | 173 (9.4) | <.001* | 172 (9.3) | 173 (9.6) | <.001* |
| SBP, mm Hg | 127 (19) | 133 (19) | 124 (18) | .001* | 135 (20) | 124 (18) | <.001* | 134 (19) | 124 (18) | <.001* |
| DBP, mm Hg | 74 (9.1) | 76 (9.6) | 73 (9.0) | <.001* | 77 (9.2) | 72 (8.8) | <.001* | 77 (9.0) | 72 (8.8) | <.001* |
| Antihypertensive Rx, n (%) | 1019 (25%) | 386 (36%) | 633 (21%) | .001* | 335 (31%) | 684 (23%) | <.001* | 347 (32%) | 672 (22%) | <.001* |
| Antihyperglycemia, n (%) | 1578 (38%) | 582 (53%) | 996 (33%) | <.001* | 546 (50%) | 1032 (34%) | <.001* | 563 (52%) | 1015 (33%) | <.001* |
| Total cholesterol, mmol/l | 4.8 (4.4–5.3) | 5.0 (4.5–5.6) | 4.7 (4.4–5.2) | <.001* | 5.0 (4.5–5.0) | 4.7 (4.4–5.3) | <.001* | 5.0 (4.5–5.5) | 4.7 (4.4–5.3) | <.001* |
| Lipid-lowering Rx, n (%) | 1169 (24%) | 394 (36%) | 775 (26%) | <.001* | 366 (33%) | 719 (24%) | <.001* | 384 (34%) | 705 (23%) | <.001* |
| Hypercholesterolemia, n (%) | 1453 (35%) | 497 (45%) | 956 (32%) | <.001* | 473 (43%) | 980 (32%) | <.001* | 477 (44%) | 976 (32%) | <.001* |
| Serum creatinine, mg/dl | 0.82 (0.23) | 0.84 (0.32) | 0.82 (0.18) | .11 | 0.85 (0.32) | 0.81 (0.19) | <.001* | 0.85 (0.32) | 0.81 (0.19) | <.001* |
| Serum cystatin C, mg/l | 0.91 (0.21) | 0.99 (0.29) | 0.88 (0.18) | <.001* | 0.98 (0.28) | 0.89 (0.18) | <.001* | 0.98 (0.28) | 0.89 (0.37) | <.001* |
| eGFR, ml/min/1.73 m² | 92 (17) | 84 (18) | 94 (16) | <.001* | 85 (18) | 94 (16) | <.001* | 85 (18) | 94 (16) | <.001* |
| UACR, mg/24 h | 8.9 (6.6–17) | 10.6 (8–22) | 8.5 (6.0–15) | <.001* | 10.6 (8–24) | 8.5 (6.0–15) | <.001* | 10.6 (8–24) | 8.5 (6.0–15) | <.001* |
| eGFR < 60 ml/min/1.73 m² | 939 (22%) | 331 (30%) | 608 (19%) | <.001* | 336 (31%) | 603 (19%) | <.001* | 340 (31%) | 599 (18%) | <.001* |
| Baseline CKD, n (%) | 202 (4.7%) | 97 (9.0%) | 105 (3.3%) | <.001* | 94 (8.8%) | 972 (31%) | <.001* | 100 (9.4%) | 102 (3.2%) | <.001* |
| Baseline eGFR < 60 ml/min/1.73 m² | 846 (18%) | 283 (25%) | 563 (16%) | <.001* | 292 (26%) | 554 (16%) | <.001* | 294 (26%) | 552 (16%) | <.001* |

SDNN = standard deviation of all normal-normal RR intervals; nMSSD = root mean square of successive differences of adjacent normal-to-normal RR intervals; HF = high-frequency power spectrum; BMI = body mass index; WHR = waist-hip ratio; SBP = systolic blood pressure; DBP = diastolic blood pressure; CVD = cardiovascular disease; Rx = medication use; eGFR = estimated glomerular filtration rate; UAE = urinary albumin excretion; CKD = chronic kidney disease, defined as eGFR < 60 ml/min/1.73 m² or UAE ≥ 30 mg/24 h.

* Significant p values (p < .05) are indicated in boldface font.
levels of eGFR in the total sample (SDNN Q1 versus Q2–Q4, unadjusted βslope difference = −0.936 ml/min/1.73 m², 95% CI = −10.6 to −8.08, p < .001, similar for other HRV measures). However, after multivariable adjustment, the association of low HRV with baseline eGFR was no longer significant (SDNN Q1 versus Q2–Q4, fully adjusted βslope difference = −0.59 ml/min/1.73 m²; 95% CI = −1.66 to 0.48, p = .28, similar for other HRV measures). During follow-up, there was no significant difference in rate of decline of eGFR between HRV categories (SDNN Q1 versus Q2–Q4, fully adjusted βslope difference = −0.077 ml/min/1.73 m² per year, 95% CI = −0.18 to 0.029, p = .16, similar for other HRV measures). Similarly, we found no significant association of HRV measures with UAE levels or increase (see Table S6a-b, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A436).

Next, we tested for a modifying effect of baseline CKD status on both level and slope by introducing their interaction terms (CKD by HRV by time; CKD by HRV; and CKD by time, in addition to their main effects) to the model. Addition of the interaction terms resulted in a significant increase in log likelihood (χ² = 64.5, Δdf = 3, pinteraction < .001 for SDNN, similar for other HRV measures), suggesting a modifying effect of baseline CKD status on the association between HRV and eGFR. Therefore, we stratified for baseline CKD status. For participants with CKD at baseline, low SDNN was associated with lower baseline eGFR. This cross-sectional association between SDNN and baseline eGFR remained after multivariable adjustment (SDNN Q1 versus Q2–Q4, fully adjusted βslope difference = −3.73 ml/min/1.73 m², 95% CI = −6.70 to −0.75, p = .014). Other HRV measures did not show an association with lower baseline eGFR in this subgroup. There were no significant associations between low HRV measures and rate of renal function decline during follow-up (SDNN Q1 versus Q2–Q4, fully adjusted βslope difference = 0.086 ml/min/1.73 m² per year, 95% CI = −0.21 to 0.38, p = .57, similar for other HRV measures). In Figure 1, we show crude and adjusted estimates of baseline eGFR level (panel A) and annual eGFR change (panel B), by SDNN category and strata according to baseline CKD status.

Sensitivity analyses in imputed data sets (see Tables S5b-c, S6c-d, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A436) yielded similar results. Application of a stricter definition of low HRV confirmed the significant result for SDNN (see Table S5a, S5c, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A436). Correlations (crude and age-adjusted) of HRV measures with kidney function outcomes reflected the results of our main analyses: (1) higher HRV correlated with higher baseline eGFR, but no longer after adjustment for age and (2) HRV showed no relevant correlations with eGFR slope (Table 6).

DISCUSSION
In this population-based, longitudinal cohort study, we examined the relation between HRV and renal outcomes. We observed an association between low HRV and higher incidence of CKD, which did not remain significant after adjustment for known CKD risk factors such as age, diabetes mellitus, and hypertension. The association between HRV and CKD risk could for a substantial part be explained by older age of those with lower HRV. An analysis of renal function over time in the total sample revealed no evidence for steeper decline in eGFR or increase in UAE in those with low HRV. In a subgroup of participants with CKD at baseline, for SDNN and a stricter definition of low HRV, we found a significant association with lower levels of baseline eGFR, which remained after adjustment for confounders, but no association with change in eGFR. For the other HRV measures (rMSSD, HF, LF, and LF/HF ratio), we did not find significant associations with either baseline levels of eGFR or decline in eGFR during follow-up in this subgroup. These results suggest that low HRV does not contribute

### TABLE 2. Distribution of HRV Parameters

| Parameter | Median (IQR) |
|-----------|--------------|
| SDNN, ms  | 31 (23–42)   |
| rMSSD, ms | 24 (17–35)   |
| HF, ms²   | 211 (94–454) |
| LF, ms²   | 242 (123–494) |
| LF/HF ratio | 1.2 (0.7–2.0) |

IQR = interquartile range; SDNN = standard deviation of normal-to-normal RR intervals; rMSSD = root mean square of successive differences; HF = high-frequency power spectrum; LF = low-frequency power spectrum.

HRV measures were nonnormally distributed; hence, data are presented as median (interquartile range).

### TABLE 3. Chronic Kidney Disease Incidence Rates by Heart Rate Variability Categories (Q1 Versus Q2–Q4)

| Category | Total | SDNN | rMSSD | HF |
|----------|-------|------|-------|----|
|          |       | Q1   | Q2–Q4 |     |
|          |       | p    |       |     |
|          |       | Q1   | Q2–Q4 |     |
|          |       | p    |       |     |
|          |       | Q1   | Q2–Q4 |     |
|          |       | p    |       |     |
|          |       | Q1   | Q2–Q4 |     |
|          |       | p    |       |     |
|          | 3397  | 849  | 2548  | NA  |
| Person-years, (IQR) | 6.1 (4.6–7.3) | 5.4 (2.1–7.3) | 6.8 (3.1–7.4) | <.001 |
| New-onset CKD, a (%) | 341 (10%) | 116 (14%) | 225 (8.8%) | <.001 |
| New-onset CKD/1000 py | 19.5 | 29.1 | 16.7 | <.001 |

SDNN = standard deviation of normal-to-normal RR intervals; rMSSD = root mean square of successive differences of adjacent normal-to-normal RR intervals; HF = high-frequency power spectrum; IQR = interquartile range; CKD = chronic kidney disease; py = person-years.

Significant p values (p < .05) are indicated in boldface font.

Event rates by HRV category (low versus moderate-to-high HRV; Q1 versus Q2–Q4).

a Defined as eGFR < 60 ml/min/1.73 m² or UAE ≥ 30 mg/24 h.

| Event rates by HRV category (low versus moderate-to-high HRV; Q1 versus Q2–Q4). | p    |
|-----------------------------------|------|
| SDNN Q1 versus Q2–Q4              | <.001 |
| rMSSD Q1 versus Q2–Q4             | <.001 |
| HF Q1 versus Q2–Q4                | .002  |

SDNN = standard deviation of normal-to-normal RR intervals; rMSSD = root mean square of successive differences of adjacent normal-to-normal RR intervals; HF = high-frequency power spectrum; IQR = interquartile range; CKD = chronic kidney disease; py = person-years.
Brotman et al. (25) did not explicitly adjust for race or report mechanisms, and stratified analyses may be warranted. Unfortunately, differences suggest as yet unknown race-specific disease mechanisms, and risk of ESRD (39). The ethnic difference, because black race has been associated with a higher cardiovascular risk profile (38) and risk of ESRD (39). The ethnic difference between the two, it is more likely to be in a reversed direction (i.e., HRV is preceded by CKD. If there is any causal relationship between low HRV and incident CKD.

To our knowledge, the only comparable population-based study of HRV and its association with renal outcomes to date was conducted by Brotman et al. (25). In a sample of 13,241 adults of the ARIC cohort, they observed that low HRV preceded CKD-related hospitalization and ESRD. In our study, we could not corroborate these findings. Several differences may explain the inconsistent results. First, the end points and available measurements used are different: our endpoint was new-onset CKD (based on repeated measurements of serum creatinine, serum cystatin C, and UAE at each subsequent examination), whereas in ARIC, the end points were CKD hospitalization and ESRD. The end points used in ARIC imply more advanced renal disease and are therefore a less suitable measure of de novo, likely mild, disease. Furthermore, because of the lack of baseline albumin measurements in their study, Brotman et al. (25) could not exclude reverse causality, that is, renal damage leading to lower HRV. Second, there is a marked difference in race composition between the two. It is more likely to be in a reversed direction (i.e., HRV is preceded by CKD). If there is any causal relationship between the two, it is more likely to be in a reversed direction (i.e., HRV is preceded by CKD).

Table 4. Association of Heart Rate Variability Measures (Q1 Versus Q2–Q4) With Incident Chronic Kidney Disease

| CKD | SDNN Q1 | p    | rMSSD Q1 | p    | HF Q1 | p    |
|-----|---------|------|----------|------|-------|------|
| Unadjusted HR (95% CI) | 1.66 (1.30−2.12) | <.001* | 1.51 (1.18−1.93) | .001* | 1.54 (1.20−1.97) | <.001* |
| Adjusted HR (95% CI)✓ | 1.02 (0.79−1.32) | .88 | 1.01 (0.78−1.30) | .97 | 0.99 (0.77−1.28) | .93 |
| Adjusted HR (95% CI)✓ | 1.10 (0.83−1.45) | .50 | 1.09 (0.82−1.45) | .57 | 1.04 (0.78−1.37) | .80 |
| Fully adjusted HR (95% CI)✓ | 1.13 (0.86−1.48) | .40 | 1.09 (0.82−1.45) | .55 | 1.02 (0.77−1.35) | .87 |
| CKD_eGFR<60 |       |      |          |      |       |      |
| Unadjusted HR (95% CI) | 2.44 (1.64−3.63) | <.001* | 1.92 (1.28−2.88) | .002* | 2.05 (1.37−3.07) | <.001* |
| Adjusted HR (95% CI)✓ | 1.05 (0.70−1.59) | .80 | 0.97 (0.64−1.46) | .88 | 0.97 (0.64−1.46) | .88 |
| Adjusted HR (95% CI)✓ | 0.90 (0.57−1.42) | .66 | 1.09 (0.68−1.75) | .71 | 0.83 (0.52−1.32) | .83 |
| Fully adjusted HR (95% CI)✓ | 0.93 (0.59−1.46) | .76 | 1.16 (0.72−1.85) | .54 | 0.89 (0.56−1.41) | .61 |
| CKD_UAE≥30 |       |      |          |      |       |      |
| Unadjusted HR (95% CI) | 1.46 (1.09−1.96) | .011* | 1.43 (1.07−1.92) | .016* | 1.39 (1.04−1.87) | .028* |
| Adjusted HR (95% CI)✓ | 1.04 (0.76−1.41) | .82 | 1.07 (0.79−1.45) | .64 | 1.01 (0.75−1.38) | .93 |
| Adjusted HR (95% CI)✓ | 1.15 (0.83−1.60) | .40 | 1.23 (0.87−1.73) | .24 | 1.12 (0.80−1.57) | .51 |
| Fully adjusted HR (95% CI)✓ | 1.17 (0.84−1.62) | .35 | 1.22 (0.87−1.71) | .25 | 1.10 (0.79−1.54) | .56 |

CKD = chronic kidney disease; SDNN = standard deviation of normal-to-normal RR intervals; rMSSD = root mean square of successive differences of adjacent normal-normal RR intervals; HF = high-frequency power spectrum; HR = hazard ratio; SDNN = standard deviation of normal-to-normal RR intervals; rMSSD = root mean square of successive differences of adjacent normal-normal RR intervals; HF = high-frequency power spectrum.

*Significant p values (p < .05) are indicated in boldface font.

✓ Adjusted for age.

† Adjusted for sex, BMI, WHR, mean interval, smoking status, baseline eGFR, baseline UAE, in addition to above.

‡ Adjusted for history of cardiovascular disease, diabetes, hypertension, and hypercholesterolemia, in addition to above.
TABLE 5. Differences Between Low (Q1) and Moderate-to-High HRV (Q2–Q4) Measures for Baseline Levels and Rate of Decline of eGFR

|                      | Total (N = 4605) | p     | No CKD (n = 3397) | p     | CKD (n = 939) | p     |
|----------------------|------------------|-------|-------------------|-------|---------------|-------|
| **SDNN Q1**          |                  |       |                   |       |               |       |
| Baseline eGFR-level difference* (ml/min/1.73 m²) |                  |       |                   |       |               |       |
| Unadjusted β (95% CI) | -9.36 (10.6 to -8.08) | .001* | -7.36 (8.56 to -6.17) | .001* | -12.3 (15.8 to -8.74) | .001* |
| Adjusted β (95% CI)^c | -0.94 (1.97 to 0.092) | .074  | -0.60 (1.59 to 0.40) | .24   | -3.52 (6.39 to -0.66) | .016* |
| Adjusted β (95% CI)^d | -0.81 (1.90 to 0.29)  | .15   | -0.43 (1.48 to 0.63) | .43   | -4.02 (-7.05 to -0.98) | .010* |
| Fully adjusted β (95% CI)^e | -0.59 (1.66 to 0.48)  | .28   | -0.42 (1.48 to 0.63) | .43   | -3.73 (-6.70 to -0.75) | .014* |
| eGFR-slope difference* (ml/min/1.73 m² per y) |                  |       |                   |       |               |       |
| Unadjusted β_slope (95% CI) | -0.068 (-0.18 to 0.039) | .21   | -0.048 (-0.16 to 0.063) | .40   | 0.080 (-0.22 to 0.38) | .60   |
| Adjusted β_slope (95% CI)^c | -0.076 (-0.18 to 0.031) | .16   | -0.061 (-0.17 to 0.050) | .28   | 0.075 (-0.22 to 0.37) | .62   |
| Adjusted β_slope (95% CI)^d | -0.072 (-0.18 to 0.034) | .18   | -0.058 (-0.17 to 0.053) | .30   | 0.078 (-0.22 to 0.37) | .60   |
| Fully adjusted β_slope (95% CI)^e | -0.077 (-0.18 to 0.029) | .16   | -0.059 (-0.17 to 0.052) | .30   | 0.086 (-0.21 to 0.38) | .57   |
| **rMSSD Q1**         |                  |       |                   |       |               |       |
| Baseline eGFR-level difference* (ml/min/1.73 m²) |                  |       |                   |       |               |       |
| Unadjusted β (95% CI) | -8.11 (-9.40 to -6.82) | .001* | -6.26 (-7.46 to -5.05) | .001* | -7.64 (-11.3 to -3.98) | .001* |
| Adjusted β (95% CI)^c | -0.70 (1.72 to 0.32)  | .18   | -0.51 (-1.48 to 0.47) | .31   | -0.98 (-3.83 to 1.87) | .50   |
| Adjusted β (95% CI)^d | -0.90 (-2.02 to 0.22)  | .11   | -0.79 (-1.87 to 0.29) | .15   | -1.42 (-4.56 to 1.71) | .37   |
| Fully adjusted β (95% CI)^e | -0.68 (-1.77 to 0.42)  | .23   | -0.83 (-1.91 to 0.25) | .13   | -1.37 (-4.43 to 1.69) | .38   |
| eGFR-slope difference* (ml/min/1.73 m² per y) |                  |       |                   |       |               |       |
| Unadjusted β_slope (95% CI) | -0.064 (-0.17 to 0.043) | .24   | -0.055 (-0.17 to 0.056) | .33   | 0.22 (-0.080 to 0.51) | .15   |
| Adjusted β_slope (95% CI)^c | -0.068 (-0.17 to 0.038) | .21   | -0.062 (-0.17 to 0.048) | .27   | 0.22 (-0.075 to 0.51) | .14   |
| Adjusted β_slope (95% CI)^d | -0.062 (-0.17 to 0.044) | .25   | -0.059 (-0.17 to 0.051) | .29   | 0.22 (-0.075 to 0.51) | .15   |
| Fully adjusted β_slope (95% CI)^e | -0.064 (-0.17 to 0.042) | .24   | -0.059 (-0.17 to 0.051) | .29   | 0.22 (-0.071 to 0.51) | .14   |
| **HF Q1**            |                  |       |                   |       |               |       |
| Baseline eGFR-level difference* (ml/min/1.73 m²) |                  |       |                   |       |               |       |
| Unadjusted β (95% CI) | -8.89 (-10.2 to -7.60) | .001* | -6.97 (-8.17 to -5.77) | .001* | -8.94 (-12.6 to -5.29) | .001* |
| Adjusted β (95% CI)^c | -0.94 (1.97 to 0.085)  | .072  | -0.66 (-1.64 to 0.32) | .19   | -1.52 (-4.38 to 1.35) | .30   |
| Adjusted β (95% CI)^d | -1.11 (-2.22 to 0.0022) | .050  | -0.82 (-1.88 to 0.24) | .13   | -1.88 (-4.96 to 1.20) | .23   |
| Fully adjusted β (95% CI)^e | -0.76 (-1.84 to 0.32)  | .17   | -0.79 (-1.85 to 0.27) | .14   | -1.62 (-4.62 to 1.39) | .17   |
| eGFR-slope difference* (ml/min/1.73 m² per y) |                  |       |                   |       |               |       |
| Unadjusted β_slope (95% CI) | -0.087 (-0.20 to 0.021) | .12   | -0.065 (-0.18 to 0.046) | .25   | 0.21 (-0.093 to 0.50) | .18   |
| Adjusted β_slope (95% CI)^c | -0.090 (-0.20 to 0.017) | .10   | -0.077 (-0.19 to 0.034) | .17   | 0.21 (-0.087 to 0.50) | .17   |
| Adjusted β_slope (95% CI)^d | -0.082 (-0.19 to 0.025) | .13   | -0.075 (-0.19 to 0.036) | .18   | 0.21 (-0.089 to 0.50) | .17   |
| Fully adjusted β_slope (95% CI)^e | -0.087 (-0.19 to 0.020) | .11   | -0.076 (-0.19 to 0.035) | .18   | 0.21 (-0.087 to 0.50) | .17   |

CKD = chronic kidney disease; SDNN = standard deviation of normal-to-normal RR intervals; eGFR: estimated glomerular filtration rate; rMSSD = root mean square of successive differences of adjacent normal-normal RR intervals; HF = high-frequency power spectrum.

Estimates of the association between low HRV and eGFR in the total PREVEND population, and stratified for CKD at baseline, from multivariable linear mixed-effects analysis. Reference group is moderate-to-high HRV (Q2–Q4).

* Significant p values (p < .05) are indicated in boldface font.

^c eGFR-level difference: difference in baseline levels of eGFR, expressed in ml/min/1.73 m², compared with reference.

^d eGFR-slope difference: difference in change in eGFR over time, in ml/min/1.73 m² per year, compared with reference.

^e Adjusted for age.

^f Adjusted for sex, BMI, WHR, mean interbeat interval, smoking status, baseline UAE, in addition to above.

^g Adjusted for history of cardiovascular disease, diabetes, hypertension, hypercholesterolemia, and (baseline chronic kidney disease status in the total cohort) in addition to above.

Psychosomatic Medicine, V 80 • 307-316 313 April 2018
measures of autonomic and renal function as well as psychological and behavioral measures in race-stratified high-risk populations. Major strengths of this study include the availability of serially measured creatinine and cystatin C–based eGFR and 24-hour UAE values, which are considered to be the best parameters to define CKD, during considerable duration of follow-up. We examined multiple measures of HRV, calculated from time series of highly standardized beat-to-beat recordings. To our knowledge, this is only the second study in the general population to examine the association of HRV with incidence of CKD and the first to assess its effect on change in eGFR and UAE. This study is therefore an important contribution to the literature.

There were several limitations. First, HRV was calculated from time series of pulse wave recordings. In individuals at rest, pulse rate variability is considered an accurate estimate of HRV (43). However, because of the lack of ECG data, we could not definitively exclude cardiac arrhythmias. Second, because follow-up HRV measurements were not available, we were unable to examine the association of HRV changes over time with renal disease or vice versa. Third, HRV was missing in approximately 33% of participants. In an effort to minimize any bias introduced by the missingness, we conducted sensitivity analyses in multiple

| TABLE 6. Correlations Between HRV Parameters and Kidney Function Outcomes |
|----------------------------------------|---------------------|---------------------|
|                                       |                       |                       |
| lnSDNN                                | 0.276***             | 0.020               |
| lnMSSD                                | 0.223***             | −0.002             |
| lnHF                                  | 0.254***             | 0.002              |
| lnLF                                  | 0.310***             | 0.040**            |
| lnLF/HF-ratio                         | 0.044**              | 0.042**            |

SDNN = standard deviation of normal-to-normal RR intervals; rMSSD = root mean square of successive differences of adjacent normal-to-normal RR intervals; HF = high-frequency power spectrum; LF = low-frequency power spectrum.

Pearson’s r and partial (age-adjusted) correlations between kidney function (eGFR and eGFR decline) and continuous, natural log (ln)-transformed HRV parameters in the total sample.

* \( p < .05 \).

** \( p < .01 \).

*** \( p < .001 \).

Correlations for eGFR slope are standardized β’s from linear mixed-effects models.
imputed data sets, the results of which did not change our conclusions. Although the missingness is likely random and non-problematic (e.g., due to technical failure, subject movement leading to artefacts in the recording), we cannot definitively rule out that in some participants, missing or invalid recordings may have been caused by nonrandom, unobserved mechanisms (e.g., cardiac arrhythmias). Fourth, estimates of GFR are less accurate in the higher range (>60 ml/min/1.73 m²). We therefore used the CKD-EPI equation for both creatinine and cystatin C, currently the best option for population-based studies (33). Fifth, we lacked specific information on β-blocking agents. This class of antihypertensive medication potentially affects both HRV and kidney function and may therefore have caused unobserved confounding. However, we estimate β-blocker user baseline prevalence to be low in this relatively healthy sample of the general population and do not expect our conclusions to be substantially affected.

These results challenge the notion that reduced HRV represents a causal factor in CKD. Rather, they suggest that reduced HRV may be a complication of CKD.

**Source of Funding and Conflicts of Interest:** The PREVEND study in general was funded by the Dutch Kidney Foundation (Grant E.033). The supporting agency had no role in the design and conduct of the study, collection, analysis or interpretation of data. All authors declare no conflict of interest.

**REFERENCES**

1. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.

2. Levey AS, Coresh J, Wang DJ, Abbott KC, Boineau R, Cai J, Chavers BM, Choudhuri V, Coresh J, Coresh J, Cryer P, Cui J, Cushman M, de Groot NM, Delahunt E, Doria A, Dj Python M, du Toit P, Dyer A, Folsom AR, Garg AX, Goto AM, Grobbee DE, Guerci AD, Hall YN, He K, Herman W, Heung M, Hirth RA, Hutton D, Jacobsen SJ, Jongejan B, Jonker T, Keenan A, Kekow J, Koenig SH, Kupferberg A, Lain S, Lameiras M, Lameiras A, Lappe J, Lazar A, Lee J, Lemaitre RN, Lemire MM, Lesperance F, Libby P, Liao J, Lin CL, Liu Q, Liu S, Lopes-Virella M, Luecken LJ, Gallo LC, editors. Handbook of Physiological Research Methods: Human Cardiopulmonary and Respiratory Systems, 2nd ed. New York: Elsevier; 2010.

3. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379:165.48

4. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, Hostetter TH. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005;16:18-80.

5. Özylmaz A, de Jong PE, Gansevoort RT. Screening for chronic kidney disease can be of help to prevent atherosclerotic end-organ damage. Nephrol Dial Transplant 2012;27:4046–52.

6. DiBona GF. Neural control of the kidney: past, present, and future. Hypertension 2004;43:699–706.

7. DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of cardiovascular activity in renal disease. Hypertension 2004;43:699–706.

8. DiBona GF. Physiological basis for and clinical utility of cardiovascular control. Science 1981;213:220–22.

9. Anonymous. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1990;93:1043–65.

10. Routledge HC, Chowdhary S, Townsend JN. Heart rate variability—a therapeutic target? J Clin Pharm Ther 2002;27:85–92.

11. Kleiger RE, Stein PK, Bigger JT Jr. Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 2005;10:88–101.

12. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol 2007;74:224–42.

13. Thayer JF, Hansen AL, Johnsen BH. Noninvasive assessment of autonomic influences on the heart: impedance cardioography and heart rate variability. In: Laukkanen LL, Gallo LC, editors. Handbook of Physiological Research Methods in Health Psychology. Thousand Oaks, CA: Sage Publications Ltd; 2008:183–209.

14. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol 2007;114(1):122–31.

15. Hillebrandt S, Gast KB, de Mutsert R, Swenne CA, Jukema JW, Middeldorp S, Rosendaal FR, Dekkers OM. Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression. European 2015:15;742–9.

16. Tory K, Siiveges Z, Horváth E, Bokor E, Tulei-Pál K, Keszthelyi A, Berta K, Szabó A, Tulassay T. Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Nephrol Dial Transplant 2003;18:318–25.

17. Burger AJ, D'Elia LA, Weinrauch L, Lamer J, Giaur A. Marked abnormalities in heart rate variability are associated with progressive deterioration of renal function in type 1 diabetic patients with overt nephropathy. Int J Cardiol 2002;86: 287–92.

18. Chandra P, Sands RL, Gillespie BW, Levin NW, Kotanko P, Kiser M, Finkelstein F, Hindelinger A, Pop-Busui R, Rajagopalan S, Saran R. Predictors of heart rate variability and its prognostic significance in chronic kidney disease. Nephrol Dial Transplant 2012;27:700–9.

19. Suzuki K, Ishihara R, Maeda T, Yamaguchi K, Koike A, Kagawauchi H, Tabata Y, Moriyama N, Ito H. Prognostic value of heart rate variability in patients with renal failure on hemodialysis. Int J Cardiol 2009;131:370–7.

20. Salman IM. Cardiovascular autonomic dysfunction in chronic kidney disease: a comprehensive review. Curr Hypertens Rep 2015;17:59.015;0571-e.

21. Brotman DJ, Bash LD, Qayyum R, Crews D, Whitsel EA, Astor BC, Coresh J. Heart rate variability predicts ESRD and CKD-related hospitalization. J Am Soc Nephrol 2010;21:1560–70.

22. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 2000;11:1882–8.

23. Munnuz ML, van Roon A, Riese H, Thio C, Oostenbroek E, Westrik I, de Geus JC, Gansevoort R, Lefrandt J, Nolte IM, Snieker H. Validity of (ultra-)short heart rate variability measurements. PLoS One 2015;10:e0138921.

24. Wesseling KH. Finapres: continuous noninvasive finger arterial pressure based on the principle of Fick. In: Meyer-Hubler A, Schäfer G, editors. Blood Pressure Measurements. 1st ed. Darmstadt: Steinkopf Verlag; 1990:161–72.

25. Mulder LJ, Roan AM, van Schweizer DA. CARSPAN: cardiovascular data analysis environment: user's manual Groningen: Icc ProGAMMA; 1995.

26. Graves-Lord K, Tullen J, Dietrich A, Sondeljuker J, van Rooyt A, Oldehinkel A, Ormel J, Verhulst F, Huiizink A. Reduced autonomic flexibility as a predictor for future anxiety in girls from the general population: The TRAILS study. Psychiatry Res 2010;179:187–93.

27. Konings SH, Gansevoort RT, Mokhamal KJ, Rimm EB, Bakker SJ, Joosten MM, PREVEND Study Group. Alcohol consumption is inversely associated with the risk of developing chronic kidney disease. Kidney Int 2015; 87:1009–16.

28. Grubel A, Blümp J, Sanders, K., Althaus H, Zegers I, IFCC Working Group on Standardisation of Cystatin C (WG-SCC). First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med 2010;48:1619–21.

29. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKD-EPI Investigators. Improved discrimination of estimated GFR using cystatin C (as compared with creatinine) in clinical studies of kidney diseases. Clin J Am Soc Nephrol 2014;9: 1226–35.

30. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007;16:219–42.

31. Hill KL, Hu KD, Koenig J, Sollers JJ 3rd, Kapuku G, Wang X, Snieker H, Thayer JF. Ethnic differences in resting heart rate variability: a systematic review and meta-analysis. Psychosom Med 2015;77:1659–78.

32. Mensah GA, Mokdad AH, Ford ES, Greenland JW, Croft JB. State of disparities in cardiovascular health in the United States. Circulation 2005;111:1233–41.

33. Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, Bragg-Gresham J, Barksnahan R, Chen JL, Cope E, Eggers PW, Gillen D, Gipson D, Halpern SM, Hall YN, He K, Herman W, Heung M, Hirth RA, Hutton D, Jacobsen SJ,
Kalantar-Zadeh K, Kovesdy CP, Lu Y, Molnar MZ, Morgenstern H, Nallamothu B, Nguyen DV, O'Hare AM, Plattner B, Pisoni R, Port FK, Rao P, Rhee CM, Sakhuja A, Schaubel DE, Selewski DT, Shahimian V, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, White S, Woodside K, Hirth RA. US Renal Data System 2015 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2016;67(3 Suppl 1):S1–305.

Rajendra Acharya U, Paul Joseph K, Kannathal N, Lim CM, Suri JS. Heart rate variability: a review. Med Biol Eng Comput 2006;44:1031–51.

Tripepi G, Jager KJ, Dekker FW, Zoëculli C. Testing for causality and prognosis: etiological and prognostic models. Kidney Int 2008;74:1512–5.

Bruce MA, Beech BM, Sims M, Brown TN, Wyatt SB, Taylor HA, Williams DR, Crook E. Social environmental stressors, psychological factors, and kidney disease. J Investig Med 2009;57:583–9.

Schäfer A, Vagedes J. How accurate is pulse rate variability as an estimate of heart rate variability? A review on studies comparing photoplethysmographic technology with an electrocardiogram. Int J Cardiol 2013;166:15–29.